WCN24-2270 COMPLEMENT SYSTEM IS OVERACTIVATED IN PATIENTS WITH IGA NEPHROPATHY AFTER COVID-19 INFECTION

WCN24-2270 COMPLEMENT SYSTEM IS OVERACTIVATED IN PATIENTS WITH IGA NEPHROPATHY AFTER COVID-19 INFECTION

Saved in:

Bibliographic Details
Main Authors:	Hong Cheng, Wei-yi Guo, Guo-qin Wang, Ling-qiang Kong, Li-jun Sun, Xiao-yi Xu, Wen-rong Cheng, Hongrui Dong
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924005229
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Clinical values of serum Gd-IgA1， complement factor H and complement regulatory proteins in IgA nephropathy
by: Zou Mei, et al.
Published: (2025-05-01)

WCN24-186 JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY
by: Mateus Luvizotto, et al.
Published: (2024-04-01)

WCN24-2606 KIDNEY RE-BIOPSY IN ADULTS WITH IGA NEPHROPATHY
by: Leonel Langellotti, et al.
Published: (2024-04-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

Exploring the causal effect of complement and IgA nephropathy—a Mendelian randomization study
by: Han Xu, et al.
Published: (2024-12-01)

WCN24-2275 GLOMERULAR GALACTOSE-DEFICIENT IGA1(KM55) POSITIVE MAY BE ASSOCIATED WITH POOR PROGNOSIS IN DKD PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

The Complement System: An Important New Therapeutic Target in IgA Nephropathy
by: Karshana J. Kalyanaraman, et al.
Published: (2024-12-01)

Clinicopathological analysis of IgA nephropathy combined with hyperuricemia
by: CAI Wei-cheng, et al.
Published: (2016-01-01)

WCN24-889 BASILIXIMAB INDUCTION, STEROID USE AND RECURRENCE OF IGA NEPHROPATHY IN RENAL TRANSPLANT PATIENTS
by: Isabela Bertoni, et al.
Published: (2024-04-01)

WCN24-1347 CLINICAL PRESENTATION AT THE TIME OF DIAGNOSIS IN A COHORT OF MEXICAN PATIENTS WITH IGA NEPHROPATHY
by: Estefania Garduño Hernandez, et al.
Published: (2024-04-01)

WCN24-1383 ADHERENCE TO INTERNATIONAL GUIDELINES FOR THE TREATMENT OF A COHORT OF MEXICAN PATIENTS WITH IGA NEPHROPATHY
by: Estefania Garduño Hernandez, et al.
Published: (2024-04-01)

WCN24-2274 CLINICOPATHOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF IDIOPATHIC MEMBRANOUS NEPHROPATHY WITH DUAL ANTIGEN POSITIVITY
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2320 ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY WITH CONCOMITANT MALIGNANCY AND LITERATURE REVIEW
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2238 EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2062 CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM PROGNOSIS OF IgA NEPHROPATHY PATIENTS WITH NEPHROTIC SYNDROME
by: xiaoling zhou, et al.
Published: (2024-04-01)

WCN24-733 Treatment decision-making modle for IgA nephropathy: a real-world study
by: Ying Zheng, et al.
Published: (2024-04-01)

WCN24-1121 Novel IgA type autoantibodies against mesangial autoantigen, βIIspectrin, are specifically detected in patients with IgA nephropathy
by: Kazuaki Mori, et al.
Published: (2024-04-01)

WCN24-2271 WARFARINRELATED NEPHROPATHY IN TWO PATIENTS WITH MECHANICAL VALVES
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2459 SARS-COV2 PROTEIN IN RENAL TISSUE ENHANCED ACTIVATION OF COMPLEMENT SYSTEM IN MN PATIENTS WITH COVID-19 INFECTION
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-743 BLIND SPOT IN THE RADAR OF MEST-C SCORE: TYPE AND SEVERITY OF TUBULOINTERSTITIAL NEPHRITIS IN IGA NEPHROPATHY
by: Aurangzeb Afzal, et al.
Published: (2024-04-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-2601 RARITY OF IGA NEPHROPATHY IN AFRICA: EVIDENCE FROM A 10YEAR REVIEW OF RENAL BIOPSIES IN EAST AFRICA - A POINTER TO THE GEOGRAPHICAL AND RACIAL DISPARITY OF IGA NEPHROPATHY IN AFRICA
by: Ahmed Kalebi
Published: (2024-04-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Relationship between renal deposition of complement C3， IgG， IgM and pathology in IgA nephropathy
by: Fang-cao Lu, et al.
Published: (2022-08-01)

WCN24-2599 EFFICACY AND SAFETY OF BUDESONIDE IN IGA NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: João Lucas de Magalhães Leal Moreira, et al.
Published: (2024-04-01)

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
by: Hernán Trimarchi, et al.
Published: (2024-04-01)

Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
by: Leonore Ingold, et al.
Published: (2025-06-01)

Systematic Review of the Link Between Oxford MEST-C Classification and Complement Activation in IgA Nephropathy
by: Gabriel Ștefan, et al.
Published: (2024-02-01)

WCN25-1435 VISUALIZATION OF THE MESANGIAL-CELL-SURFACE AUTOANTIGENS IN IGA NEPHROPATHY
by: Kazuaki Mori, et al.
Published: (2025-02-01)

WCN25-4525 IGA NEPHROPATHY CLINICOPATHOLOGICAL ASSOCIATION WITH MEST-C SCORING
by: Meghana Rao C, et al.
Published: (2025-02-01)

WCN24-1104 Finding of CD4+ T cells infiltrating the kidney of gddY mouse, IgA nephropathy animal model
by: Hiroyuki Iwasaki, et al.
Published: (2024-04-01)

WCN24-1565 EFFECT OF PHOSPHODIESTERASE V INHIBITOR ON FIBROBLAST DERIVED FROM BIOPSY SPECIMEN OF IgA NEPHROPATHY: AN IN-VITRO STUDY
by: Manas Ranjan Behera, et al.
Published: (2024-04-01)

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2024-04-01)

Urine complement analysis implies complement activation is involved in membranous nephropathy
by: Yingxue Xu, et al.
Published: (2025-02-01)

WCN25-4505 A DESCRIPTIVE STUDY ON THE CLINICOPATHOLOGICAL PROFILE AND TREATMENT OUTCOME OF IgA NEPHROPATHY USING THE INTERNATIONAL IgA NEPHROPATHY PREDICTION TOOL
by: Arghya Chakraborty, et al.
Published: (2025-02-01)

WCN24-2410 “ASSOCIATION OF GLOMERULAR SYNDROMES WITH HISTOLOGICAL FINDINGS ACCORDING TO THE MEST-C SCORE OF THE OXFORD CLASSIFICATION IN PATIENTS WITH IgA NEPHROPATHY”
by: NIDIAANAHIMOLINA GONZÁLEZ, et al.
Published: (2024-04-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)